Home » Newsletters » BioWorld Science

BioWorld Science

June 5, 2018

View Archived Issues

Mouse models of high-grade bladder cancer for in vivo evaluation of immunotherapy presented

Bayer Animal Health discovers anthelmintic compounds

GS-0976 demonstrates significant hepatic effects in patients with NASH cirrhosis

Hepagene Therapeutics describes farnesoid X receptor agonists

MALT1-targeting compounds synthesized by the Dana-Farber Cancer Institute and collaborators

Prelude Therapeutics identifies PRMT5 inhibitors

Myalepta receives positive CHMP opinion for generalized and partial lipodystrophy

Cyxone chooses to complete acquisition of rabeximod

GERD candidate X-842 safe and well tolerated in first-in-human study

Dynavax Technologies presents Toll-like receptor 7/8/9 antagonists

First-in-human results from Millennium's TAK-931 in advanced solid tumors

PFK/FBPase 1 inhibitors identified at Merck KGaA

Zenith advances trial of ZEN-3694 in metastatic CRPC into phase II

Evoke submits NDA to the FDA for Gimoti

FDA accepts NDA filing for bremelanotide for hypoactive sexual desire disorder

Interim results presented from phase I trial of PIN-2 in patients with solid tumors

Versartis and Aravive Biologics enter merger agreement

FDA approves pegfilgrastim biosimilar Fulphila

FDA clears Nant to begin clinical trials with neoepitope yeast vaccine YE-NEO-011

Clovis seeks to expand use of Rubraca in E.U. in recurrent ovarian cancer

Isomer discovery could yield countless new drugs

Mabion submits MAA for rituximab biosimilar Mabion-CD20

Perjeta approved in E.U. for adjuvant treatment of HER2-positive early breast cancer

Yakult licenses rights to duvelisib in Japan

Primary efficacy endpoint not achieved in phase II study of teslexivir gel in condyloma

FDA grants priority review to Hemlibra sBLA

Preclinical study shows Cynata's MSCs are effective in model of diabetic ulcers

CytRx launches new subsidiary Centurion Biopharma

Researchers present first-in-human data for Bayer's BAY-1251152 in advanced cancers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.